However, higher plasma concentrations of Lp(a), albeit within the normal range, could be an independent risk women) were studied and compared with 89 controls (36 men and 53 women) matched in terms of age, sex, body factor for atherosclerosis, and could contribute towards increasing the incidence of cardiovascular disease in mass index (BMI) and smoking habits. It was found that the hypertensive patients had higher plasma concenpeople with essential arterial hypertension.
Introduction
diseases such as CHD [24] [25] [26] [27] [28] [29] [30] [31] and the re-stenosis of corMany studies have shown clearly that high concenonary bypass [32] [33] [34] [35] but are also considered an indetrations of low-density lipoproteins (LDL-C), Apolipendent risk factor for these pathologies. poprotein B (Apo B) and total cholesterol (TC) Up to now there is very little information on Lp(a) accompanied by low concentrations of high-density in hypertensive patients available in the literature, lipoproteins (HDL-C) and Apoprotein AI (Apo AI) and any results published are contrasting. [36] [37] [38] [39] [40] [41] are the main risk factors for coronary heart disease Therefore, the aim of our study was to measure (CHD), [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] and there is considerable evidence that the serum concentrations of lipoproteins, and in all measures which are capable of lowering LDL-C particular of Lp(a) in a group of untreated hypertenand raising HDL-C concentrations also help to lower sive patients with no clinical signs of associated the incidence of acute events in these patients. 16 In pathologies or organ damage and no family histories patients with essential hypertension there are often of coronary or cerebrovascular atherosclerotic discardiovascular risk factors. Indeed, in these patients, ease. a modification of the lipid profile has been observed, with increased levels of total cholesterol, triglycer-
Materials and methods
ides and LDL-C and low blood concentrations of HDL-C.
17-19

Patients
The lipoprotein(a) Lp(a) was described for the first A total of 123 Caucasian patients (47 men and 76 time in 1963 by Berg. 20 It consists of a set of lipoprowomen) with essential arterial hypertension [systeins with different molecular weights (from 350 to tolic blood pressure (SBP) 165 ± 1.5 mm Hg and 900 KD), 21 in which particles of LDL are bonded to diastolic blood pressure (DBP) 101 ± 0.4 mm Hg] apoprotein(a) (apo(a)), which has a kringle structure were studied. Their average age was 53 ± 9 and their with a high level of homology to plasminogen. 22, 23 average body mass index (BMI) was 25.4 ± 3.9. They The physiological function of this lipoprotein is still included 14 smokers (11%), but no former smokers. unknown but the importance attributed to it has
The diagnosis of essential hypertension was reached increased considerably in the light of the evidence after repeatedly measuring the patients' arterial that high plasma concentrations of Lp(a) are not pressure at different times of the day using a mercury sphygmomanometer (Korotkoff sounds I and V) 46 Lastly, Lp(a) was assayed using two different anti-Apo(a) antibodies, the first (AST Ͼ25 IU/L, ALT Ͼ29 IU/L, total bilirubin Ͼ1.2 mg/dl, ␥-GT Ͼ38 IU/L) or thyroid functions of which was a monoclonal solid-phase antibody, while the second was polyclonal, and marked with (TSH Ͻ0.5 U/ml or 3.5 U/ml) and uricemia Ͼ5.7 mg/dl for the female and Ͼ7 mg/dl for the male a peroxidase (Macra Enzyme Immunoassay kit: Terumo Medical Corporation, Strategic Diagnosis patients, were excluded.
Eighty-nine Caucasian subjects (36 men and 53 Division, Elkton, MD 21921, USA). 47 The inter-and intra-assay coefficients of variations for Lp(a) were women) with no clinically evident pathologies and originating from the same geographical area were 3.1-1.3%, respectively. The lowest measurable Lp(a) concentration was calculated to be 0.8 mg/dl. used as a control group. They were matched with the hypertensive patients in terms of age (51 ± 3), sex, BMI (24.8 ± 3.4) and smoking habits (11 smokStatistical analysis ers = 12%) (see Table 1 ). For the purpose of this
In order to choose the most appropriate statistical study, the patients did not receive any drugs capable test, the variables were tested for skewness. Thanks of altering their lipid profiles for at least 4 weeks to this preliminary statistical evaluation, it was before taking the blood samples. They were given established that, with the exception of Lp(a), all the no dietary restrictions. The hypertensive patients variables in question had a sufficiently normal disand the controls all came from Medical Angiology tribution. or Internal Medicine out-patient departments.
For this reason, the statistical analysis was performed using analysis of variance (ANOVA) and
Blood samples
Tukey's test, and in view of the skewed distribution of blood Lp(a) concentrations in the hypertensive The blood samples for determining the apolipoprotand normal subjects we applied the Mann-Whitein profiles were taken at 8.00 am, without stasis, ney test. by inserting a needle into the vein after fasting and The 2 test was used for the non-parametric varirefraining from cigarette smoking for at least 12 h.
ables. Values of P Ͻ 0.05 were considered significant.
Determination of the apolipoprotein profile
The correlations between Lp(a) and all the remaining parameters studied were checked using The samples for determining the plasma concenthe Spearman Correlation Test, taking Lp(a) as an trations of total cholesterol, triglyceride, VLDL-C, independent variable. LDL-C, HDL-C, Apoproteins AI, AII and B and Lp(a) were placed in pre-cooled test tubes containing EDTA (1 mg/ml) and centrifuged immediately at Results 1500 g for 15 min at a temperature of 4°C. The Table 1 describes the main clinical characteristics of plasma obtained in this way was then frozen and the essential hypertensive patients and of the norstored at −85°C, and assayed within 2 weeks after mal controls. The two groups were similar in terms sampling. TC and TG were assayed using enzyme of age, sex, smoking habits and BMI, while the avermethods, with kits supplied by Boehringer age systolic and diastolic BP values were higher in (Mannheim, Germany). 43, 44 The HDL-C concenthe patients with essential hypertension. tration was measured after precipitation of the lipo- Table 2 , on the other hand, shows the plasma conproteins containing Apo B with phosphotungstic acid and subsequent enzymatic assaying of choles- Table 2 Apolipoprotein profile of normotensives and hypertenterol. 45 The inter-and intra-assay coefficients of vari- male patients (female Lp(a) range 0.8-95.7 mg/dl, median value 7.6 mg/dl; male Lp(a) range 0.8-43.2 mg/dl, median value 7.5 mg/dl). Only 10 of the hypertensive patients (8.1%) and seven of the normal controls (7.8%) had plasma concentrations of Lp(a) higher than 30 mg/dl (Figure 1) . Table 3 shows the coefficients of correlation between Lp(a) and all the other parameters studied. No correlation was noted between Lp(a) and the main parameters of the lipid profile.
Conclusions
This study shows the plasma concentrations of Lp(a) and of the main parameters of the lipid profiles of patients with essential hypertension with no other clinically evident pathologies. The first result emerging from this investigation consists of significantly higher plasma concentrations of Lp(a) in the hypertensive patients than in the healthy controls. Although they found no differences in the concen- trations of Lp(a) and in the apo(a) phenotypes between hypertensive patients and controls, some authors pointed out a positive correlation between high Lp(a) concentrations (characterised by isoforms of apo(a) with a low molecular weight) and a positive family history of CHD in the hypertensive patients. In the past, it has also been observed that the had Lp(a) concentrations falling with what are defined as normal values for this lipoprotein, and only a very minor portion of them (8.1%) had Lp(a) values exceeding 30 mg/dl (these were considered high risk patients for aterothrombotic diseases). These higher values could not be explained by the presence of a family history of CHD.
In fact, our study called for patients with essential arterial hypertension with no clinical signs of pathologies or organ damage and with no family histories of CHD.
Thus, the higher concentrations of Lp(a) in the hypertensive patients than in the controls, could constitute a first pathological sign, in the absence of noticeable organ damages.
CHD and stroke are the main causes of morbidity and mortality in patients with arterial hypertension 50 and in many studies Lp(a) has been found to be an important risk factor for cardiovascular disease.
51-53 The mechanisms by means of which Lp(a) increases the risk of thrombosis is not completely clear. Some observations that Lp(a) concentrates in the atherosclerotic plaques by means of mechanisms similar to those described for oxidised or modified LDLs.
Indeed, in its protein fraction, in addition to apo(a), Lp(a) also contains a certain quantity of Apo dation, and can also undergo phagocytosis by the monocytic and macrophagous cells through specific receptors, with the formation of 'foam cells'. 54 In addition, through apo(a), Lp(a) is capable of bonding with the fibronectin 55 present in early atheromatous lesions and also with the glycosaminoglycans present in the arterial walls. [56] [57] [58] It seems that this lipoprotein can be retained in the sub-intimal space of the arteries longer than LDL, with consequent greater atherogenicity.
58, 59 It has also been shown that there is a close correlation between high serum concentrations of Lp(a) and the concentrations of apo(a) in the arterial wall.
60 Lp(a) can also modulate operation of the fibrinolytic mechanism.
61 Indeed, it may even be capable of stimulating the synthesis of PAI-1. 62 Although in vivo studies have given rise to contrasting results, it has been possible to observe in vitro that Lp(a) inhibits activation of the plasminogen to plasmin, 63, 64 and is capable, thanks to apo(a), of bonding with the tissue activator of plasminogen (t-PA), reducing its capacity to activate plasminogen to a significant extent. 65 These observations indicate that Lp(a) could also have a considerable atherogenic and thrombogenic potential, and the fact that we found higher serum concentrations of this lipoprotein in the hypertensive patients studied could be considered a negative including hypocholesterolaemic drugs, are incapable of influencing its concentrations in the plasma. Therefore Lp(a) is a risk factor which cannot plasma concentrations of Lp(a) are inversely correlated with the size of the apo(a) isoforms. High be controlled. In addition, the suggestion that this lipoprotein is plasma concentrations of Lp(a) are therefore associated with low molecular weight apo(a) isoforms and an independent risk factor is confirmed by the fact that Lp(a) is not correlated either with age or with with a higher cardiovascular risk.
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On the other hand, most of the patients studied the main parameters of the lipid profile (Table 3) . patients with arterial hypertension tend, generally
